cilostazol has been researched along with Diabetes Mellitus, Adult-Onset in 50 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare prevention by cilostazol and aspirin of progression of atherosclerosis, we conducted a prospective, randomized, open, blinded end point study in 4 East Asian countries." | 9.14 | The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. ( Katakami, N; Kawamori, R; Kim, YS; Yamasaki, Y, 2010) |
| "To evaluate the effects of cilostazol, an antiplatelet and vasodilation agent, on the retinal function of patients with non-proliferative diabetic retinopathy (NPDR) using a full-field electroretinogram (ffERG)." | 7.83 | The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients. ( Kim, HD; Kim, YK; Lee, SH; Oh, JR; Ohn, YH, 2016) |
| "These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats." | 7.71 | The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. ( Ahn, YB; Cha, BY; Chang, SA; Han, JH; Kang, MI; Kang, SK; Lee, JM; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH, 2001) |
| "Body weight and abdominal fat was increased in OLETF rats but cilostazol supplementation did not alter them." | 7.70 | Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM. ( Harada, N; Minami, A; Nakamura, T; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S, 1999) |
| "Cilostazol is an antiplatelet, antithrombotic agent with anti-inflammatory properties." | 6.79 | Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. ( Hsiao, FC; Hsieh, CH; Hung, YJ; Kuo, FC; Lee, CH; Lin, FH; Tang, WH, 2014) |
| " Safety parameters were changes in nerve conduction studies as well as reporting of adverse events." | 6.76 | Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of diabetes mellitus type 2 (ASCEND). ( Mercado-Asis, LB; Rosales, RL; Santos, MM, 2011) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 6.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "Patients with type 2 diabetes and arteriosclerosis obliterans from the Eastern Asian countries were registered online and randomly assigned either to the aspirin group (81-100 mg/day) or the cilostazol group (100-200 mg/day) in this international, 2-year, prospective follow-up interventional study." | 6.72 | Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study). ( Kawamori, R; Kim, YS; Yamasaki, Y, 2006) |
| "Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication." | 6.47 | Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? ( Corrado, E; Mikhailidis, DP; Patti, AM; Rini, GB; Rizzo, M, 2011) |
| "Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy." | 5.72 | Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022) |
| "After the end of the ESCAPE study with patients with type 2 diabetes mellitus (T2DM) and mild to moderate coronary artery stenosis, we decided to extend the ESCAPE study to investigate the long-term effect of cilostazol and aspirin, named the ESCAPE-extension study." | 5.51 | Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study. ( Chun, EJ; Lim, S; Sohn, M, 2022) |
| "Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications." | 5.22 | Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. ( Manolis, AA; Manolis, AS; Manolis, TA; Melita, H; Mikhailidis, DP, 2022) |
| "To compare prevention by cilostazol and aspirin of progression of atherosclerosis, we conducted a prospective, randomized, open, blinded end point study in 4 East Asian countries." | 5.14 | The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. ( Katakami, N; Kawamori, R; Kim, YS; Yamasaki, Y, 2010) |
| "To evaluate the effects of cilostazol, an antiplatelet and vasodilation agent, on the retinal function of patients with non-proliferative diabetic retinopathy (NPDR) using a full-field electroretinogram (ffERG)." | 3.83 | The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients. ( Kim, HD; Kim, YK; Lee, SH; Oh, JR; Ohn, YH, 2016) |
| "These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats." | 3.71 | The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. ( Ahn, YB; Cha, BY; Chang, SA; Han, JH; Kang, MI; Kang, SK; Lee, JM; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH, 2001) |
| "Body weight and abdominal fat was increased in OLETF rats but cilostazol supplementation did not alter them." | 3.70 | Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM. ( Harada, N; Minami, A; Nakamura, T; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S, 1999) |
| "We randomly assigned 116 patients with type 2 diabetes and cardiovascular risk factors but no evident cardiovascular disease to receive aspirin at a dose of 100 mg or cilostazol at a dose of 200 mg daily for 14 days." | 3.11 | Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease. ( Hong, S; Lee, WJ; Park, CY, 2022) |
| "Fifty patients with T2D and carotid atherosclerotic plaques were randomly assigned to either a 200 mg/d cilostazol (CTZ) group or a 100 mg/d aspirin (ASA) group for 6 months." | 2.94 | Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: The FANCY study. ( Chun, EJ; Lee, DH; Lim, S; Moon, JH; Yun, HM, 2020) |
| "Cilostazol treatment was associated with significantly lowered IMT in T2D patients compared to aspirin, independent of conventional cardiovascular risk factors." | 2.90 | Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. ( Chun, M; Hong, S; Kang, J; Kim, D; Lee, K; Little, BB; Nam, M; Paik, S; Park, Y; Woo, J, 2019) |
| "Cilostazol is an antiplatelet, antithrombotic agent, which has been used for the treatment of PAOD." | 2.80 | Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. ( Chen, JH; Chuang, TJ; Hsiao, FC; Hsieh, CH; Hung, YJ; Lee, CH; Lin, TK; Liu, JS, 2015) |
| "Cilostazol is an antiplatelet, antithrombotic agent with anti-inflammatory properties." | 2.79 | Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. ( Hsiao, FC; Hsieh, CH; Hung, YJ; Kuo, FC; Lee, CH; Lin, FH; Tang, WH, 2014) |
| " Safety parameters were changes in nerve conduction studies as well as reporting of adverse events." | 2.76 | Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of diabetes mellitus type 2 (ASCEND). ( Mercado-Asis, LB; Rosales, RL; Santos, MM, 2011) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 2.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "Patients with type 2 diabetes and arteriosclerosis obliterans from the Eastern Asian countries were registered online and randomly assigned either to the aspirin group (81-100 mg/day) or the cilostazol group (100-200 mg/day) in this international, 2-year, prospective follow-up interventional study." | 2.72 | Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study). ( Kawamori, R; Kim, YS; Yamasaki, Y, 2006) |
| "Cilostazol is an anti-thrombotic and vasodilating agent, reported to have both anti-thrombotic and cerebral vasodilating effects." | 2.71 | Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. ( Hamazaki, T; Johkaji, H; Kobayashi, M; Minami, S; Nakamura, N; Okomura, K; Osawa, H; Satoh, A; Sawazaki, S; Urakaze, M; Yamabe, H; Yamazaki, K, 2003) |
| "Since antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients is very important after intracoronary stenting, and because the most commonly used therapies have been the dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel and the triple antiplatelet therapy (TAPT) consisting of aspirin, clopidogrel and cilostazol, we aim to compare the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in T2DM patients." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "Individuals with either type 2 diabetes (DM2) or pre-diabetes have microvascular dysfunction that contributes to morbidity and mortality." | 2.47 | Erythrocytes as controllers of perfusion distribution in the microvasculature of skeletal muscle. ( Achilleus, D; Bowles, EA; Ellsworth, ML; Sprague, RS, 2011) |
| "Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication." | 2.47 | Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? ( Corrado, E; Mikhailidis, DP; Patti, AM; Rini, GB; Rizzo, M, 2011) |
| "Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy." | 1.72 | Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022) |
| "In patients with type 2 diabetes, cilostazol prevents the progression of subclinical coronary atherosclerosis." | 1.72 | Cardiovascular Protection Associated With Cilostazol, Colchicine, and Target of Rapamycin Inhibitors. ( Adeva-Andany, MM; Carneiro-Freire, N; Castro-Quintela, E; Fernández-Fernández, C; González-Lucán, M; Vila-Altesor, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (10.00) | 18.2507 |
| 2000's | 12 (24.00) | 29.6817 |
| 2010's | 26 (52.00) | 24.3611 |
| 2020's | 7 (14.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manolis, AA | 1 |
| Manolis, TA | 1 |
| Melita, H | 1 |
| Mikhailidis, DP | 2 |
| Manolis, AS | 1 |
| Gomaa, AA | 1 |
| Farghaly, HSM | 1 |
| Ahmed, AM | 1 |
| El-Mokhtar, MA | 1 |
| Hemida, FK | 1 |
| Hong, S | 2 |
| Lee, WJ | 1 |
| Park, CY | 1 |
| Adeva-Andany, MM | 1 |
| Fernández-Fernández, C | 1 |
| Carneiro-Freire, N | 1 |
| Castro-Quintela, E | 1 |
| Vila-Altesor, M | 1 |
| González-Lucán, M | 1 |
| Sohn, M | 1 |
| Chun, EJ | 2 |
| Lim, S | 2 |
| Lee, DH | 1 |
| Moon, JH | 1 |
| Yun, HM | 1 |
| Lee, CY | 1 |
| Wu, TC | 1 |
| Lin, SJ | 1 |
| Wang, Z | 1 |
| Liu, T | 1 |
| Chen, X | 1 |
| You, H | 1 |
| Zhang, Q | 1 |
| Xue, J | 1 |
| Zheng, Y | 1 |
| Luo, D | 1 |
| Nam, M | 1 |
| Little, BB | 1 |
| Paik, S | 1 |
| Lee, K | 1 |
| Woo, J | 1 |
| Kim, D | 1 |
| Kang, J | 1 |
| Chun, M | 1 |
| Park, Y | 2 |
| Tang, WH | 1 |
| Lin, FH | 1 |
| Lee, CH | 2 |
| Kuo, FC | 1 |
| Hsieh, CH | 2 |
| Hsiao, FC | 2 |
| Hung, YJ | 2 |
| Araki, S | 1 |
| Matsuno, H | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Kanno, Y | 1 |
| Kume, S | 1 |
| Isshiki, K | 1 |
| Araki, H | 1 |
| Ugi, S | 1 |
| Kawai, H | 1 |
| Kashiwagi, A | 1 |
| Uzu, T | 1 |
| Maegawa, H | 1 |
| Ha, SJ | 1 |
| Kim, SJ | 1 |
| Hwang, SJ | 2 |
| Woo, JS | 1 |
| Kim, W | 1 |
| Kim, WS | 1 |
| Kim, KS | 1 |
| Kim, MK | 2 |
| Jiao, XM | 1 |
| Jiao, XJ | 1 |
| Zhang, XG | 1 |
| Xu, XP | 1 |
| Wu, JX | 1 |
| Yao, L | 1 |
| Zhao, J | 1 |
| Lü, XF | 1 |
| Huh, JH | 1 |
| Seok, H | 1 |
| Lee, BW | 1 |
| Kang, ES | 1 |
| Lee, HC | 2 |
| Cha, BS | 1 |
| Aoki, Y | 1 |
| Shimizu, M | 2 |
| Watanabe, N | 1 |
| Birnbaum, Y | 3 |
| Nanhwan, MK | 1 |
| Ling, S | 3 |
| Perez-Polo, JR | 3 |
| Ye, Y | 3 |
| Bajaj, M | 3 |
| Kwon, KJ | 1 |
| Lee, EJ | 1 |
| Kim, SY | 1 |
| Kim, JN | 1 |
| Kim, JO | 1 |
| Kim, HJ | 1 |
| Kim, HY | 1 |
| Han, JS | 1 |
| Shin, CY | 1 |
| Han, SH | 1 |
| Liu, JS | 1 |
| Chuang, TJ | 1 |
| Chen, JH | 1 |
| Lin, TK | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Kim, HD | 1 |
| Lee, SH | 1 |
| Kim, YK | 1 |
| Oh, JR | 1 |
| Ohn, YH | 1 |
| Tsukamoto, Y | 1 |
| Nagata, E | 1 |
| Fukuyama, N | 1 |
| Itoh, Y | 1 |
| Yuzawa, H | 1 |
| Kohara, S | 1 |
| Takahari, Y | 1 |
| Takizawa, S | 1 |
| Angiolillo, DJ | 2 |
| Capranzano, P | 2 |
| Goto, S | 1 |
| Aslam, M | 1 |
| Desai, B | 2 |
| Charlton, RK | 1 |
| Suzuki, Y | 1 |
| Box, LC | 1 |
| Shoemaker, SB | 1 |
| Zenni, MM | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Matsumoto, T | 1 |
| Noguchi, E | 1 |
| Ishida, K | 1 |
| Nakayama, N | 1 |
| Kobayashi, T | 1 |
| Kamata, K | 1 |
| Park, SY | 1 |
| Shin, HK | 1 |
| Lee, JH | 1 |
| Kim, CD | 1 |
| Lee, WS | 1 |
| Rhim, BY | 1 |
| Hong, KW | 1 |
| Hsieh, CJ | 1 |
| Wang, PW | 1 |
| Katakami, N | 1 |
| Kim, YS | 4 |
| Kawamori, R | 3 |
| Yamasaki, Y | 3 |
| Sprague, RS | 2 |
| Bowles, EA | 2 |
| Achilleus, D | 2 |
| Ellsworth, ML | 2 |
| Rhee, SY | 1 |
| Chon, S | 1 |
| Oh, S | 1 |
| Woo, JT | 1 |
| Kim, SW | 1 |
| Kim, JW | 1 |
| Rizzo, M | 1 |
| Corrado, E | 1 |
| Patti, AM | 1 |
| Rini, GB | 1 |
| Yang, TH | 1 |
| Kim, DI | 1 |
| Kim, DK | 2 |
| Jang, JS | 1 |
| Kim, U | 1 |
| Seol, SH | 1 |
| Hong, GR | 1 |
| Park, JS | 1 |
| Shin, DG | 1 |
| Kim, YJ | 1 |
| Cho, YK | 1 |
| Nam, CW | 1 |
| Hur, SH | 1 |
| Kim, KB | 1 |
| Kim, DS | 1 |
| Rosales, RL | 1 |
| Santos, MM | 1 |
| Mercado-Asis, LB | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 1 |
| Capodanno, D | 1 |
| Stephenson, AH | 1 |
| Ellis, CG | 1 |
| Jeong, YH | 1 |
| Tantry, US | 1 |
| Kwon, TJ | 1 |
| Park, JR | 1 |
| Bliden, KP | 1 |
| Koh, EH | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Kim, S | 1 |
| Gurbel, PA | 1 |
| Castillo, AC | 2 |
| Qian, J | 2 |
| Ye, H | 2 |
| Huisamen, B | 1 |
| Ikewaki, K | 1 |
| Mochizuki, K | 1 |
| Iwasaki, M | 1 |
| Nishide, R | 1 |
| Mochizuki, S | 1 |
| Tada, N | 1 |
| Nakamura, N | 1 |
| Hamazaki, T | 1 |
| Johkaji, H | 1 |
| Minami, S | 1 |
| Yamazaki, K | 1 |
| Satoh, A | 1 |
| Sawazaki, S | 1 |
| Urakaze, M | 1 |
| Kobayashi, M | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Okomura, K | 1 |
| Mitsuhashi, N | 1 |
| Tanaka, Y | 1 |
| Kubo, S | 1 |
| Ogawa, S | 1 |
| Hayashi, C | 1 |
| Uchino, H | 1 |
| Shimizu, T | 1 |
| Watada, H | 1 |
| Kawasumi, M | 1 |
| Onuma, T | 1 |
| Agrawal, NK | 1 |
| Maiti, R | 1 |
| Dash, D | 1 |
| Pandey, BL | 1 |
| Tani, N | 1 |
| Hada, K | 1 |
| Kitami, A | 1 |
| Nakano, M | 1 |
| Takahashi, H | 1 |
| Ito, S | 1 |
| Sato, I | 1 |
| Shibata, A | 1 |
| Hotta, N | 2 |
| Koh, N | 2 |
| Sakakibara, F | 2 |
| Nakamura, J | 2 |
| Hamada, Y | 2 |
| Hara, T | 2 |
| Mori, K | 2 |
| Naruse, K | 1 |
| Fukasawa, H | 1 |
| Kakuta, H | 1 |
| Sakamoto, N | 1 |
| Nakashima, E | 1 |
| Sasaki, H | 1 |
| Kasama, N | 1 |
| Inukai, S | 1 |
| Nomura, S | 1 |
| Shouzu, A | 1 |
| Omoto, S | 1 |
| Hayakawa, T | 1 |
| Kagawa, H | 1 |
| Nishikawa, M | 1 |
| Inada, M | 1 |
| Fujimura, Y | 1 |
| Ikeda, Y | 1 |
| Fukuhara, S | 1 |
| Ahn, CW | 1 |
| Park, SW | 1 |
| Song, YD | 1 |
| Huh, KB | 1 |
| Oh, SJ | 1 |
| Choi, YK | 1 |
| Kim, JM | 1 |
| Lee, TH | 1 |
| Nakaya, Y | 1 |
| Minami, A | 1 |
| Sakamoto, S | 1 |
| Niwa, Y | 1 |
| Ohnaka, M | 1 |
| Harada, N | 1 |
| Nakamura, T | 1 |
| Chang, SA | 1 |
| Cha, BY | 1 |
| Yoo, SJ | 1 |
| Ahn, YB | 1 |
| Song, KH | 1 |
| Han, JH | 1 |
| Lee, JM | 1 |
| Son, HS | 1 |
| Yoon, KH | 1 |
| Kang, MI | 1 |
| Lee, KW | 1 |
| Son, HY | 1 |
| Kang, SK | 1 |
| Shinoda-Tagawa, T | 1 |
| Yoshida, S | 1 |
| Kajimoto, Y | 1 |
| Tsujino, T | 1 |
| Hakui, N | 1 |
| Matsumoto, M | 1 |
| Hori, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients[NCT02933788] | Phase 4 | 116 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| Effect of Cilostazol, a Phosphodiesterase 3 Inhibitor, on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes[NCT03248401] | Phase 4 | 50 participants (Actual) | Interventional | 2016-09-26 | Completed | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention[NCT01012193] | Phase 4 | 134 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for cilostazol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
Topics: Animals; Cilostazol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Erythrocytes as controllers of perfusion distribution in the microvasculature of skeletal muscle.
Topics: Adenosine Triphosphate; Animals; Caffeine; Cilostazol; Diabetes Mellitus, Type 2; Erythrocytes; Huma | 2011 |
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?
Topics: Atherosclerosis; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus, Type 2 | 2011 |
21 trials available for cilostazol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study.
Topics: Aspirin; Cilostazol; Coronary Artery Disease; Coronary Stenosis; Diabetes Mellitus, Type 2; Drug The | 2022 |
Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: The FANCY study.
Topics: Carotid Intima-Media Thickness; Cilostazol; Diabetes Mellitus, Type 2; Female; Humans; Male; Plaque, | 2020 |
Effects of Postoperative Percutaneous Coronary Intervention, Pharmacologic Treatment, and Predisposing Factors on Clinical Outcomes in Patients With and Without Type 2 Diabetes Along With Critical Limb Ischemia.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Diabetes Mellitus, Type 2; Extremities; F | 2021 |
Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Carotid Intima-Media Thickness; Cilostazol | 2019 |
Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Albuminuria; Anti-Inflammatory Agents; Chemokine CCL2; Cil | 2014 |
Cilostazol attenuates spontaneous microaggregation of platelets in type 2 diabetic patients with insufficient platelet response to aspirin.
Topics: Aged; Aspirin; Cilostazol; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Aggregation; Pl | 2013 |
Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
Topics: Blood Platelets; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over | 2013 |
Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy.
Topics: Albuminuria; Cilostazol; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Tetrazoles | 2013 |
Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.
Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Arterial Occlusive Diseases; C-Reactive Protein; Cilo | 2015 |
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove | 2008 |
Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease.
Topics: Adiponectin; Aged; Aged, 80 and over; Ankle; Arterial Occlusive Diseases; Biomarkers; Blood Pressure | 2009 |
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Topics: Aged; Atherosclerosis; Carotid Artery Diseases; Cilostazol; Diabetes Mellitus, Type 2; Female; Human | 2010 |
Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of diabetes mellitus type 2 (ASCEND).
Topics: Adolescent; Adult; Aged; Cilostazol; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response | 2011 |
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Apolipoprotein A-I; Apolipoproteins E; Cholesterol; Cilostazol; | 2002 |
Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.
Topics: Aged; Apolipoproteins; Arteriosclerosis; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Fasti | 2003 |
Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.
Topics: Aged; Arteriosclerosis; Blood Pressure; Carotid Arteries; Cholesterol; Cilostazol; Diabetes Mellitus | 2004 |
Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study).
Topics: Atherosclerosis; Cilostazol; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Internationality; | 2006 |
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood Sedimentation; C-Reactive Protein; Cardiovascular Dise | 2007 |
Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Blood Pressure; Carotid Artery, Common; Cilostazol; Coronary Disease; Diabetes Mellit | 2001 |
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes.
Topics: Aged; Asian People; Carotid Arteries; Cerebral Infarction; Cilostazol; Diabetes Mellitus, Type 2; Di | 2002 |
25 other studies available for cilostazol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia.
Topics: Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Caffeine; Cilostazol; Diabetes Mellitus, | 2022 |
Cardiovascular Protection Associated With Cilostazol, Colchicine, and Target of Rapamycin Inhibitors.
Topics: Cilostazol; Colchicine; Coronary Artery Disease; Cyclic AMP; Diabetes Mellitus, Type 2; Humans; Musc | 2022 |
Low molecular weight fucoidan ameliorates hindlimb ischemic injury in type 2 diabetic rats.
Topics: Animals; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relat | 2018 |
Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event.
Topics: Aged; Cardiovascular Diseases; Carotid Arteries; Carotid Intima-Media Thickness; Cilostazol; Diabete | 2014 |
The blood glucose level increased in parallel with the heart rate following cilostazol administration in three diabetic patients.
Topics: Aged, 80 and over; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Female; Heart Rate; Humans; | 2014 |
PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins.
Topics: Animals; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Diet, Western; Fluorobenzenes; Gene K | 2014 |
Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Carotid Artery Diseases; Caspase 3; Cell Death; C | 2015 |
The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients.
Topics: Adult; Aged; Analysis of Variance; Atherosclerosis; Case-Control Studies; Cilostazol; Diabetes Melli | 2016 |
Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes.
Topics: Animals; Brain Injuries; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis | 2017 |
Cilostazol improves endothelial dysfunction by increasing endothelium-derived hyperpolarizing factor response in mesenteric arteries from Type 2 diabetic rats.
Topics: Acetylcholine; Animals; Biological Factors; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experimental; | 2008 |
Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Animals; Biomarkers; Blood Glucose; Body Weight; Cilostaz | 2009 |
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty | 2011 |
Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Cilostazol; Clopidogrel; Cor | 2011 |
Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Hum | 2012 |
A selective phosphodiesterase 3 inhibitor rescues low PO2-induced ATP release from erythrocytes of humans with type 2 diabetes: implication for vascular control.
Topics: Adenosine Triphosphate; Adult; Animals; Arterioles; Case-Control Studies; Cilostazol; Cricetinae; Cy | 2011 |
Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.
Topics: Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Percutaneous Coronary Inte | 2012 |
Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.
Topics: Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Percutaneous Coronary Inte | 2012 |
Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.
Topics: Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Percutaneous Coronary Inte | 2012 |
Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.
Topics: Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Percutaneous Coronary Inte | 2012 |
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Melli | 2012 |
Cyclic AMP and PKA: how can a lot of good come from the potentially bad? : editorial to: "phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus" by Y
Topics: Animals; Cilostazol; Cyclic AMP; Diabetes Mellitus, Type 2; Male; Myocardial Infarction; Phosphodies | 2012 |
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
Topics: Animals; Blood Glucose; Blotting, Western; Cholesterol; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent | 2013 |
Effects of acetyl salicylic acid and cilostazol administration on serum thrombomodulin concentration in diabetic patients.
Topics: Aged; Aspirin; Cilostazol; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Male; M | 1993 |
Nerve function and blood flow in Otsuka Long-Evans Tokushima Fatty rats with sucrose feeding: effect of an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Alcohols; Animals; Anticoagulants; Blood Glucose; Body Weight; Carbohydrate | 1996 |
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Aldehyde Reductase; Animals; Anticoagulants; Blood Glucose; Body Weight; Cil | 1997 |
Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Cell Adhesion Molecules; Cilostazol; Diabetes Melli | 1998 |
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Topics: Abdomen; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cilostazol; Diabetes Mellitus, Type 2; | 1999 |
The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus.
Topics: Animals; Animals, Newborn; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Disease Models, Ani | 2001 |